Corpus overview


MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


SARS-CoV-2 Proteins
    displaying 1 - 1 records in total 1
    records per page

    A Novel SARS-CoV-2 Multitope Protein/Peptide Vaccine Candidate is Highly Immunogenic and Prevents Lung Infection in an Adeno Associated Virus Human Angiotensin-Converting Enzyme 2 HGNC (AAV hACE2 HGNC) Mouse Model

    Authors: Farshad Guirakhoo; Lucy Kuo; James Peng; Juin Hua Huang; Ben Kuo; Feng Lin; Kevin Liu; Zhi Liu; Grace Wu; Shuang Ding; Lou-Liang Hou; Jennifer Cheng; Vicky Yang; Hank Jiang; Jason Wang; Tony Chen; WeiGuo Xia; Ed Lin; Chung Ho Hung; Kate Chen; Zhonghao Shih; Yilin Lin; Brandon T. Schurter; Mei Mei Hu; Gray Heppner; Delphine C. Malherbe; Alexander Bukreyev; Michael Hellerstein; Thomas Monath; Chang Yi Wang

    doi:10.1101/2020.11.30.399154 Date: 2020-11-30 Source: bioRxiv

    In this report, we describe the initial development and proof-of-concept studies for UB-612, the first multitope protein-peptide vaccine against Severe Acute Respiratory Syndrome Coronavirus 2 MESHD (SARS-CoV-2), the pathogen responsible for the Coronavirus Disease MESHD of 2019 ( COVID-19 MESHD). UB-612 consists of eight components rationally designed for induction of high neutralizing antibodies and broad T cell responses against SARS-CoV-2: the S1-RBD-sFc fusion protein, six synthetic peptides (one universal peptide and five SARS-CoV-2-derived peptides), a proprietary CpG TLR-9 HGNC agonist, and aluminum phosphate adjuvant. Through immunogenicity studies in guinea pigs and rats, we optimized the design of protein/peptide immunogens and selected an adjuvant system, yielding a vaccine that provided excellent S1-RBD binding and high neutralizing antibody responses, robust cellular responses, and a Th1-oriented response at low doses of the vaccine. Our candidate vaccine was then advanced into challenge studies, in which it reduced viral load and prevented development of disease in a mouse challenge model and in nonhuman primates (NHP, immunogenicity part is completed, challenge is ongoing). A GLP-compliant toxicity MESHD study has shown a favorable safety profile for the vaccine. With the Phase 1 trial ongoing in Taiwan and additional trials planned worldwide, UB-612 is a highly promising and differentiated vaccine candidate for prevention of SARS-CoV-2 transmission and COVID-19 MESHD disease.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.